Several response criteria have recently been proposed that include PSMA PET scan-CT and are as follows:“Response evaluation criteria in PSMA PET/CT scan” (RECIP) to assess the efficacy profile of PSMA-ligand treatment in patients with mCRPC, developed in a multicenter retrospective trial at three academic medical centers, considering not only the number of new lesions but also changes in tumor volume [69]. This evidence concerns the gene FOLH1 and neoplasm.